ZOMDF (Zomedica) Shiller PE Ratio: (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Zomedica Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Zomedica  (OTCPK:ZOMDF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Zomedica Shiller PE Ratio Related Terms


Zomedica Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Zomedica's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zomedica Shiller PE Ratio Chart

Zomedica Annual Data
Trend Feb15 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Zomedica Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ZOMDF vs SERA, CVRX, RPID: Shiller PE Ratio Comparison

For the Medical Devices subindustry, Zomedica's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zomedica Shiller PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zomedica's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Zomedica's Shiller PE Ratio falls into.



Zomedica Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Zomedica's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Zomedica's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.0038/333.9520*333.9520
=-0.004

Current CPI (Jun. 2026) = 333.9520.

Zomedica Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201606 -0.010 241.018 -0.014
201609 -0.010 241.428 -0.014
201612 -0.040 241.432 -0.055
201703 -0.020 243.801 -0.027
201706 -0.020 244.955 -0.027
201709 -0.020 246.819 -0.027
201803 -0.020 249.554 -0.027
201806 -0.040 251.989 -0.053
201809 -0.020 252.439 -0.027
201812 -0.086 251.233 -0.115
201903 -0.116 254.202 -0.152
201906 -0.022 256.143 -0.029
201909 -0.026 256.759 -0.034
201912 -0.026 256.974 -0.034
202003 -0.021 258.115 -0.027
202006 -0.025 257.797 -0.032
202009 -0.009 260.280 -0.012
202012 -0.007 260.474 -0.008
202103 -0.005 264.877 -0.006
202106 -0.005 271.696 -0.006
202109 -0.007 274.310 -0.008
202112 -0.003 278.802 -0.004
202203 -0.004 287.504 -0.005
202206 -0.005 296.311 -0.006
202209 -0.005 296.808 -0.006
202212 -0.003 296.797 -0.003
202303 -0.007 301.836 -0.007
202306 -0.005 305.109 -0.006
202309 -0.001 307.789 -0.001
202312 -0.023 306.746 -0.025
202403 -0.009 312.332 -0.010
202406 -0.024 314.175 -0.026
202409 -0.007 315.301 -0.007
202412 -0.007 315.605 -0.008
202503 -0.065 319.799 -0.068
202506 -0.008 322.561 -0.008
202509 -0.006 324.800 -0.006
202512 -0.005 324.054 -0.005
202603 -0.005 330.213 -0.005
202606 -0.004 333.952 -0.004

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zomedica Business Description

Address 1101 Technology Drive, Suite 100, Ann Arbor, MI, USA, 48108
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.